arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Liminatus Pharma, Inc.

LIMN

$3.98 ▼ -0.10 (-2.33%) at close

11 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Liminatus Pharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $192.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -362.4% ↘

FCF / Share $-0.02 ↗

Trailing P/E —

Price / Book 741.1x

FCF Yield —

Debt / Equity 4.80

info Valuation on last close. End-of-day price, Sep 23, 2026.

11-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-1.12M

↓ -243.1% —

FCF / Share Free cash flow per share

$-0.02

↑ +64.2% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

Financial Health ↑

100

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	—	-50.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-3300.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-133.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	100.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	99.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-243.1% Weak ↑ Weak Improving Year-over-year change in net income	-243.1% Weak ↑ Weak Improving Year-over-year change in net income	-3455.5% Weak ↑ Weak Improving Year-over-year change in net income	81.3% Excellent ↑ Excellent Improving Year-over-year change in net income	81.3% Excellent Excellent Year-over-year change in net income	-132501.6% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	—	-514.6% Weak Weak Year-over-year change in free cash flow	—	-88.8% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.79x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.05x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.83x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.49x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.12x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.00x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-362.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	655.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	7.1% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	33.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	10.0% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	1.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	0.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	2.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	3.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	30.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-40.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-172.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-52.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-3.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	—	—	83.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+455%)	19.9% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+33%)	3.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-75%)	1.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-89%)	1.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-92%)	9.2% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-39%)	9.5% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-37%)	38.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+155%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Debt to Equity (x)	4.80x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+700%)	-10.88x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-1913%)	-0.15x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-124%)	-0.88x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-246%)	-0.16x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-127%)	—	-1.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-272%)	—	—	—	—
Net Debt (USD)	$1.44M	$1.44M	$1.44M	$1.44M	$1.44M	—	$19.97M	—	—	—	—
Debt / EBITDA (x)	-1.05x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.31x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.63x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-2.06x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.29x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-119.54x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Basic EPS, GAAP (USD)	$-0.03	$-0.03	$-0.34	$-0.07	$0.00	$-0.02	$-0.01	$-0.03	$-0.05	$-2.47	—
Free Cash Flow per Share (USD)	$-0.02	$-0.06	—	$-0.02	—	$-0.01	—	$-0.01	$-0.06	—	—
Book Value per Share (USD)	$0.01	$-0.00	$-0.36	$-0.06	$-0.34	$-1.12	$-1.11	$-1.09	$-1.06	—	—
Tangible Book Value per Share (USD)	$0.01	$-0.00	$-0.36	$-0.06	$-0.34	$-1.12	$-1.11	$-1.09	$-1.06	—	—
Basic Weighted Avg Shares (shares)	48.40M	36.00M	—	27.01M	23.30M	17.50M	—	17.50M	17.50M	100	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$352.04K	$-110.88K	$-9.80M	$-1.66M	$-8.73M	—	$-19.47M	—	—	—	—
Total Equity (USD)	$300.61K	$-132.60K	$-9.81M	$-1.65M	$-8.81M	$-19.67M	$-19.34M	$-19.11M	$-18.51M	$-647.00	$-15.79M

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Depreciation Expense (USD)	$468.00	$518.00	$543.00	$542.00	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-1.12M	$-1.12M	$-8.17M	$-327.53K	$-327.53K	$-327.53K	$-229.75K	$-1.75M	$-1.75M	$-247.00	—
Operating Cash Flow (USD)	$-970.00K	$-2.02M	$-386.85K	$-600.61K	—	$-159.39K	$-140.66K	$-206.12K	$-1.10M	$0.00	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 3 years · 11 quarters

Liminatus Pharma, Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare LIMN with peers